

Name : Dr.Sheela Godbole
Designation : Scientist 'E'
Department : Epidemiology & Biostatistics
Email Address : sgodbole@nariindia.org



Education Qualifications :

Degree / Subject	Year	Institution / University
PG Diploma in Epidemiology	2014	Public Health Foundation of India
MD (Dermatology, Venereology and Leprology)	1992	Byramjee Jeejeebhoy (B.J.) Medical College, University Of Pune.
MBBS (Medicine and Surgery)	1988	Byramjee Jeejeebhoy (B.J.) Medical College, University of Pune

Areas of Interest:

Epidemiology of HIV and STI's, Surveillance and HIV estimations; Impact Evaluation; Clinical Trials for HIV treatment and Prevention; HIV and Cancer including HIV and HPV; STI/RTI and Women's health. Teaching and Training.

Awards and Honors:

1. Selected as an ICMR fellow for the **"Collaborative Indo-Swedish Public Health Initiative for Research Excellence" (INSPIRE) Indo-Swedish Program in 2011-12**
2. **"Young Achievers Award for Women"**: for contributions in the field of Health and Medicine in Pune City. 4th January 2003 in Pune, for contributions to the field of Health and Medicine in Pune over the last decade.
3. **"Best Participant award"**: WHO Disease Burden Workshop 2001.
4. **"A. C. Parikh award for Best Case Paper presentation"**, presented by Indian Association of Dermatologists and Venereologists Maharashtra Branch 1992.

Membership of Other Professional / Advisory Bodies / Committees:

National

- 2016 Member National Core Group on Elimination of Mother to Child transmission of HIV and Syphilis in India- NACO, MoHFW
- 2012 Member Regional STI Centre National Mentoring Committee NACO (MOHFW)
- 2015-16 Member Expert Committee for National guidelines for HIV Testing NACO (MOHFW)
- 2010-15 Expert Assessor: Assessment Of STI Regional Research Laboratories
 Member of the following NACO Technical Resource Group's for India's National AIDS Control Program IV planning
- a. Sexually Transmitted Infections Working group and STI Surveillance sub-group
 - b. Research and Evaluation: Strategic Information Management Unit Sub Group
- Member: National Expert Consultation for the development of a Strategy towards Elimination of Congenital Syphilis (ECS)-
- 2006-09 Member Ethics Committee: UDIRT, Maharashtra University of Health Sciences (MUHS)

International:

- 2004 Prevention Science Working Group
- 2004-07 AACTG Women's Health Committee
- 2011-13 Women at Risk (WaTR) Scientific Committee of HPTN

Research Experience

Ongoing Research Support:

- Title:** "An assessment of feasibility of operationalization of 'Early or Immediate ART' to HIV infected partner as a combination intervention among HIV serodiscordant couples in India.
Role: Principal Investigator **Sponsor:** National AIDS Control Organisation, India
Goal: Multicentre - Implementation Research to inform roll-out of 'Test and Treat' among HIV serodiscordant couples in India's antiretroviral treatment (ART) centres under the National AIDS Control Program
- Title:** HIV Sentinel Surveillance and Integrated Biological and Behavioural Surveillance (Western and Central India): Program-research.
Role: Nodal Officer **Sponsor:** National AIDS Control Organisation
Goal: Ascertain trends in HIV prevalence through sentinel surveillance among different population subgroups like antenatal clinic attendees (ANC), STD patients, Female Sex Workers, Men having Sex with Men (MSM), Transgender, Intravenous Drug Users, Migrants, in 5 Indian states and 2 Union territories in Western India. District categorization, HIV Burden Estimation

Research Support Approved to be funded:

- Title:** 'The ART Impact Evaluation- India Study (ARTIE-India): Evaluation of Impact of Antiretroviral Therapy under the National AIDS Control Programme in India'
Role: Principal Investigator **Sponsor:** National AIDS Control Organisation
Goal: To evaluate the National and regional impact of India's free Antiretroviral therapy (ART) access program across India and its impact on goals of the program (Mortality, morbidity, stigma)
- Title:** ' Network Driven Community based HIV Testing model – A Demonstration Project for the sex worker community '
Role: Principal Investigator **Sponsor:**Swasti – BMGF Avahan-III
Goal: To assess the feasibility of developing a 'Sex worker- Network' driven HIV Testing model to reach the unreached and hidden sex workers and test the untested.- A demonstration project
- Title:** "Prevalence of Select Sexually Transmitted infections and reproductive Tract infections among selected High Risk Groups: MSM, FSW, IDU in India"
Role: Principal Investigator **Sponsor:** National AIDS Control Organisation
Goal: Multicentre National Study on Prevalence of Sexually Transmitted and Reproductive tract infections in 5 different regions of India covering 10 states

Completed Research Support

- Title:** "Clinical Trial Unit"
Role: Principal Investigator **Sponsor:** NIH [3UM1A1069417-07S2]
- Title:** *HPTN 052:A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care alone to prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples*
Role: Site PI/ IOR **Sponsor and Budget:** HPTN GRANT: FCO 794/ID 0080 0228 UNDER HPTN –MGA-NARI-I
Goal: Long term safety of 'Early ART' for prevention of transmission of HIV in serodiscordant couples
Enrolled 175 discordant couples with 98% retention at the end of 10 years. This study was a game changer for HIV Prevention

3. **Title:** HIV Database and Cancer Registry Match Pilot Study:
Goal: To demonstrate the feasibility of a computerized HIV Database and Cancer Registry Match, and identify spectrum of cancers among HIV infected persons in India
Role: Co-Principal Investigator India, **Funding:** UCLA- CFAR and Intramural
4. **Title:** *Prevalence of anal HPV infections and associated abnormalities in HIV infected women: A feasibility study [Intramural]*
Outcome: Established feasibility and determined the prevalence of anal HPV infection in HIV infected women and described the specific HPV types associated with anal infection among them .
Role: Principal Investigator
5. **Title:** **ACTG 5282:** A Randomized, Phase II Trial to Compare an HPV Test-and-Treat Strategy to a Cytology based Strategy for Prevention of CIN 2+ in HIV-infected Women
Role: Site PI at the NARI CTU. **Funding:** NIH (CTU grant)
Goal: To compare a human papillomavirus (HPV) test-and- treat strategy with a cytology-based strategy. All participants will be screened with the Abbott Real Time high-risk HPV test (aHPV) to detect high-risk HPV (hr-HPV) infection a phase II study
6. **Title:** Utility of Prevention-of-Mother-to-Child HIV Transmission Program Data for HIV Surveillance
Role: NARI-Lead Investigator (Co- INV) **Funding:** NACO
7. **Title:** Exploring attitudes and behavioural issues related to anal sex and other sexual practices among HIV infected women respondents of the anal HPV prevalence study
Role: Principal Investigator/Intramural

Contributions to Science

1. HIV Prevention (ART):

Primary sexual partners are most at risk of HIV and in India monogamous women married to persons with HIV showed a very high incidence of HIV. Dr. Godbole has been a co-investigator for microbicide trials at NARI in the previous decade. However, in the absence of an efficacious vaccine and in low HIV prevalence settings, prevention strategies that benefit the HIV infected (treatment) as well as the persons at risk (prevention) will prove to be the most cost effective methods of controlling HIV infection.

She was the site IOR for the HPTN 052 study in Pune India, an RCT to assess the efficacy of Early ART for HIV prevention, which ended in 2015 and has been a game-changer in HIV treatment as well as prevention. After the landmark HPTN 052 study, Dr. Godbole is currently leading a multicentre implementation project in the states of Maharashtra and Gujarat to address feasibility of 'test and treat' for HIV discordant couples at ART centres in India in order to inform program roll out.

2. The changing epidemiology of HIV in various populations at high risk and HIV Surveillance:

In spite of a high overall burden, the HIV epidemic in India is concentrated among various subpopulations at risk while it remains at low level in the general population. Understanding the changing epidemiology among these populations is key to development of preventive interventions. Dr. Godbole has been part of India's surveillance program since 2006, and is currently the Nodal officer overseeing HIV Sentinel Surveillance for 7 states/UT in Western India. The various initiatives by her group to improve quality of surveillance included piloting implementation of random sampling methods for surveillance among HRG. Her group analyses data from surveillance and Integrated Biological and Behavioural surveillance to understand the changing epidemic and inform NACP.

3. Understanding the spectrum of Cancer in HIV in India:

Conducted the first ever HIV database and Cancer Registry Match study in Pune India, in association with NCI and UCLA and Mumbai Cancer Society, demonstrating feasibility and revealing a substantial burden. Incidence of cervical and anal cancers were found to be manifold higher among HIV infected women. We also studied the type specific prevalence of HPV in the anal and cervical regions of such women. The group at NARI continues to work on HPV and cancers among PLHIV

4. Impact Evaluation of Interventions; Estimations and Modeling of HIV :

Estimation of the burden of HIV in different populations is necessary not only for policy and planning, they are often required for advocacy. She was involved as a team-lead in state level HIV estimations as part of the Nation HIV estimations (Report published by NACO) in 2012-3. Modeling and Estimations are also integral to Evaluation of Impact of Intervention Programs and she was involved as a consultant for the WB funded evaluation of Targeted Intervention Program in 2010-11. Dr. Godbole has just been approved for a grant for a GFATM mandated Impact Evaluation of ART Intervention in India. This is a high profile nation-wide multicentre project for which a regional network of Institutions and consultants has been developed.

5. Improving HIV Clinical care:

HIV clinical care along with cancer therapeutics is one of the fastest growing fields and emergent data are always required to improve treatment outcomes. As PI/IO of HPTN 052 study and as a co-investigator in the ACTG/NIH funded PEARLS study, she has been able to provide data on clinical outcomes and drug resistance in Early ART as well as assess different regimens for HIV treatment. As a co-investigator cohort studies among HIV discordant couples and Long term Non Progressors she has contributed to knowledge on clinical outcomes and immune-pathogenesis.

Publications:

1. "Development of IFN- γ secretory ELISPOT based assay for screening of ADCC responses." Shete A, Suryawanshi P, Chavan C, Kulkarni A, **Godbole S**, Ghate M and Thakar M. *Journal of Immunological methods* 2016 Dec 5. [Epub ahead of print]
2. "Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package." Bhatnagar T, Dutta T, Stover J, **Godbole S**, Sahu D, Boopathi K, Bembalkar S, Singh KJ, Goyal R, Pandey A, Mehendale SM. *PLoS One*. 2016 Oct 6;11(10):e0164001.
3. "HIV and Cancer Registry Linkage identifies a Substantial Burden of Cancers in Persons with HIV in India". **Sheela V Godbole** et al **Medicine** 95: 37, September 2016
4. "Antiretroviral Treatment for Prevention of HIV Transmission: The Final Results of the HIV Prevention Trials Network (HPTN) 052 Trial". M S. Cohen, Y.Q. Chen, M McCauley, T. Gamble, M.C.Hosseini pour, N. Kumarasamy, J.G. Hakim, J.Kumwenda, B Grinsztejn, J.H.S. Pilotto, **S.V. Godbole.**, S.Chariyalertsak, B.R. Santos, K H. Mayer, I F. Hoffman, S.H. Eshleman, E Piwowar-Manning, L. Cottle, X.C. Zhang, J. Makhema, L.A. Mills, J. Eron, J. Gallant, D.Havlir, S. Swindells, V.Elharrar, D Burns, T.E.Taha, K.Nielsen-Saines, D Celentano, M. Essex, S.E. Hudelson, A.D.Redd.and T. R. Fleming, for the HPTN 052 Study Team* **New England Journal of Medicine** **18 July 2016** online first DOI: 10.1056/NEJMoa1600693
5. "HIV infected CD4+ T cells use T-bet dependent pathway for production of IL-10 upon antigen recognition". *Scandinavian Journal of Immunology* 83(4):288-296 · May 2016 DOI: 10.1111/sji.12422. Shete A, Suryawanshi P, **Godbole S**, Pawar J, Paranjape R, Thakar M

6. *"HIV drug resistance in adults failing early antiretroviral treatment"*.JAIDS Journal of Acquired Immune Deficiency Syndromes · February 2016 DOI: 10.1097
Fogel, Jessica M.; Hudelson, Sarah E.; Ou, San-San; Hart, Stephen; Wallis, Carole; Morgado, Mariza G.; Saravanan, Shanmugam; Tripathy, Srikanth; Hovind, Laura; Piwowar-Manning, Estelle Sabin, Devin; McCauley, Marybeth; Gamble, Theresa; Zhang, Xinyi Cindy; Eron, Joseph J.; Gallant, Joel E.; Kumwenda, Johnstone; Makhema, Joseph; Kumarasamy, Nagalingeswaran; Chariyalertsak, Suwat; Dr.; Hakim, James; Badal-Faesen, Sharlaa; Akelo, Victor; Hosseinipour, Mina C.; Santos, BrenoRiegel; **Godbole, Sheela V**; Pilotto, Jose Henrique; Grinsztejn, Beatriz; Panchia, Ravindre ; Mayer, Kenneth H.; Chen, Ying Q.; Cohen, Myron S.; Eshleman, Susan H

7. *"Fallacy of Using Odds Ratio As A Measure Of Association In Prospective Studies."*Asian J Sc Tech. 2015; 6(11):1990-92 30 Nov 2015. Rajneesh K Joshi, MonilAnuragKhera and **Sheela V. Godbole**

8. *"Predictors of Bisexual Behaviour among MSM Attending Intervention Sites May Help in Prevention Interventions for This Bridge to the Heterosexual Epidemic in India: Data from HIV Sentinel Surveillance"***Godbole S**, Sane S, Kamble P, Raj Y, Dulhani N, et al. (2014) **PLoS ONE** 9(9): e107439. doi: 10.1371/journal.pone.0107439

9. *"Prevalence of anal Human papillomavirus (HPV) infection among HIV-infected women from India."***Sheela V. Godbole**,Arati K. Mane, Shweta R. Chidrawar, Usha R. Katti, Shubhangi Kalgutkar, PrachiV.Athavale, Jyoti S. Pawar, Manisha M. Ratnaparkhi, Mallika Alexander, Arun R. Risbud, Ramesh S.Paranjape, **JAIDS** Journal of Acquired Immune Deficiency Syndromes Published Ahead of Print a DOI: 10.1097/QAI.0000000000000328 5th Sep 2014

10. *"Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial"* Beatriz Grinsztejn, Mina C Hosseinipour, Heather J Ribaldo, Susan Swindells, Joseph Eron, Ying Q Chen, Lei Wang, San-San Ou, Maija Anderson, Marybeth McCauley, Theresa Gamble, NagalingeswaranKumarasamy, James G Hakim, JohnstoneKumwenda, Jose H S Pilotto, **Sheela V Godbole**,SuwatChariyalertsak, MarineideGonçalves de Melo, Kenneth H Mayer, Susan H Eshleman, Estelle Piwowar-Manning, Joseph Makhema, Lisa A Mills, RavindrePanchia, Ian Sanne, Joel Gallant, Irving Hoff man, Taha E Taha, Karin Nielsen-Saines, David Celentano, Max Essex, Diane Havlir, Myron S Cohen, and the HPTN 052-ACTG Study Team. **Lancet Infectious Diseases**,Volume 14, Issue 4, Pages 281 - 290, April 2014 [http://dx.doi.org/10.1016/S1473-3099\(13\)70692-](http://dx.doi.org/10.1016/S1473-3099(13)70692-)

11. *"Cost-Effectiveness of HIV Treatment as Prevention in Serodiscordant Couples"* Rochelle P. Walensky, M.D., M.P.H., Eric L. Ross, B.A., NagalingeswaranKumarasamy, M.B., B.S., Ph.D., Robin Wood, D.Sc., FarzadNoubary, Ph.D., A. David Paltiel, Ph.D., M.B.A., Yoriko M. Nakamura, B.A., **Sheela V. Godbole, M.D.**,RavindrePanchia, M.B., B.Ch., Ian Sanne, M.B., B.Ch., D.T.M.&H., Milton C. Weinstein, Ph.D., Elena Losina, Ph.D., Kenneth H. Mayer, M.D., Ying Q. Chen, Ph.D., Lei Wang, Ph.D., Marybeth McCauley, M.P.H., Theresa Gamble, Ph.D., George R. Seage, III, D.Sc., M.P.H., Myron S. Cohen, M.D., and Kenneth A. Freedberg, M.D.**Engl J Med** 2013;**369:1715-1725October 31, 2013**

12. *"Self-Report of STI Symptoms, Inconsistent Condom use and Condom Nonuse are Poor Predictors of STI Prevalence among Men who have Sex with Men".* Nagarajan K, **Godbole S***,Ramakrishnan L, Mainkar MK, Ramesh S, DeepikaGanju Ramesh S Paranjape (2013)**Journal of AIDS & Clinical Research**4:212. doi: 10.4172/2155-6113.1000212 2013

13. *'Risk reduction and perceived collective efficacy and community support among female sex workers in Tamil Nadu and Maharashtra, India: the importance of context.'* MohuaGuha, Angela Baschieri, ShaliniBharat,TarunBhatnagar, Suvarna Sanjay Sane, **Sheela V Godbole**,Saravanamurthy P S,MandarKeshavMainkar, Joseph Williams, Martine Collumbien. **JECH** Online First, published on July 3, 2012 as 10.1136/jech-2011-200562
14. *'Current Status of Research on HIV Epidemic, Pathogenesis, Management and Prevention in India.'* Ramesh S. Paranjape, Madhuri R. Thakar, Manisha V. Ghate and **Sheela V. Godbole**. **Proceedings of the National Academy of Sciences**, India Section B 2012; 82(1): 167-180
15. *'Sexually Transmitted Infections and Risk Behaviors Among Transgender persons (Hijras) of Pune, India'.* Sahastrabuddhe S, Gupta A, Stuart E, **Godbole S**, Ghate M, Sahay S, Gangakhedkar R, Risbud A, Divekar A, Bollinger R, Mehendale S. **J Acquir Immune Defic Syndr** 2012 Jan 1; **59(1):72-8**.
16. *"Prevention of HIV-1 Infection with Early Antiretroviral Therapy."* Myron S. Cohen, Ying Q. Chen, Marybeth McCauley, Theresa Gamble, Mina C. Hosseinipour, Nagalingeswaran Kumarasamy, James G. Hakim, Johnstone Kumwenda, Beatriz Grinsztejn, Jose H.S. Pilotto, **Sheela V. Godbole**., Sanjay Mehendale, Suwat Chariyalertsak, Breno R. Santos, Kenneth H. Mayer, Irving F. Hoffman, Susan H. Eshleman, Estelle Piwowar-Manning, Lei Wang, Joseph Makhema, Lisa A. Mills, Guy de Bruyn, Ian Sanne, Joseph Eron, Joel Gallant, Diane Havlir, Susan Swindells, Heather Ribaud, Vanessa Elharrar, David Burns, Taha E. Taha, Karin Nielsen-Saines, David Celentano, Max Essex, and Thomas R. Fleming, for the HPTN 052 Study Team* **New England Journal of Medicine** 2011, **10.1056/NEJMoa1105243**) July 18, 2011, at **NEJM.org**.
17. *"Impact of Targeted Interventions on Heterosexual Transmission of HIV in India."* Rajesh Kumar, Sanjay M Mehendale, Samiran Panda, S Venkatesh, Pvm Lakshmi, Manmeet Kaur, Shankar Prinja, Tarundeep Singh, Navkiran K Viridi, Pankaj Bahuguna, Arun K Sharma, Samiksha Singh, **Sheela V Godbole**, Arun Risbud, Boymkesh Manna, V Thirumagal, Tarun Roy, Ruchi Sogarwal, Nilesh D Pawar. **BMC Public Health** 2011, **11:549**
18. *"Mortality in HIV infected individuals in Pune, India."* Manisha Ghate, Swapna Deshpande, Srikanth Tripathy, **Sheela Godbole**, Madhura Nene, Madhuri Thakar, Arun Risbud, Robert Bollinger & Sanjay Mehendale. **Indian J Med Res** **133**, April 2011, pp 414-420
19. *"Stigmatizing attitudes and low levels of knowledge but high willingness to participate in HIV Management: A community-based survey of pharmacies in Pune, India."* Amita Gupta, Suvarna S Sane, Ajay Gurbani, Robert C Bollinger, Sanjay M Mehendale, **Sheela V Godbole**. **BMC Public Health** 2010, **10:51**
20. *"Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts."* Ghate M, Deshpande S, Tripathy S, Nene M, Gedam P, **Godbole S**, Thakar M, Risbud A, Bollinger R, Mehendale S. **International Journal of Infectious Diseases**.(2009)**13**, e1-e8
21. *"HIV Infection in India : Epidemiology, molecular epidemiology and pathogenesis."* Samir Lakhshashe, Madhuri Thakar, **Sheela Godbole**, Srikanth Tripathy and Ramesh Paranjape.**Journal of Biosciences** Nov 2008; **33 (4) : 515-525**
22. *"Biomedical research on HIV/AIDS in India."***Sheela Godbole**& Sanjay Mehendale published on the web at **www.infochangeindia.org** in February 2008.

23. *"Declining HIV incidence among patients attending Sexually transmitted Infection Clinics in Pune, India."* Sanjay M Mehendale, Nikhil Gupte, Ramesh Paranjape, Amita Gupta, Radhika Brahme, Rewa Kohli, Neelam Joglekar , **Sheela V Godbole**, Smita N Joshi Manisha V Ghate, Seema Sahay, B Kishore Kumar, Raman R Gangakhedkar, Arun R Risbud, Ron Brookemeyer, Robert C Bollinger **J Acquir ImmuneDefic Syndr, Aug 15 2007 (45),5, 564-569**
24. *"Issues in managing and coordinating clinical research in India."***Godbole, S.,& Ghate, M. (2006). Research Practitioner, 7(6), 219-220**
25. *"Same sex behaviour and high rates of HIV among men attending sexually transmitted infection clinics in Pune, India, 1993-2002."* Amita Gupta, Shruti Mehta, **Sheela V Godbole**, Seema Sahay, Louise Walshe, Steven J Reynolds, Manisha Ghate, Raman R Gangakhedkar, Anand Divekar, Arun R Risbud, Sanjay M Mehendale, Robert C Bollinger **J Acquir ImmuneDefic Syndr epub Oct 2 2006**
26. *"High Rates of Syphilis among STI Patients are Contributing to the Spread of HIV-1 In India."* Steven. J Reynolds, Arun R. Risbud, Mary.E. Shepherd, Anne M. Rompalo, Manisha V. Ghate, **Sheela V. Godbole**, Smita N Joshi, Anand D Divekar, Raman R. Gangakhedkar, Robert C. Bollinger, and Sanjay M Mehendale. **Sex Transm Infections 2006;82:121-126**
27. *"Rate of hospitalization and inpatient care costs for HIV-1 infected persons in Pune, India."* Ghate MV, Tripathy SP, Kumar BK, **Godbole SV**, Chitakke A, NyanirguneP,Thakar MR, Gangakhedkar RR, Divekar AD, Risbud AR, Bollinger RC, Mehendale SM. **Nat Med J India 2006; 19(1):10-14**
28. *"Low HIV incidence among married serodiscordant couples in Pune, India."* Mehendale S M, Ghate M V, Kumar BK, Sahay S, Gamble TR, **Godbole SV**, Thakar MR, Kulkarni SS, Gupta A, Gangakhedkar RR, Divekar AD, Risbud AR, Paranjape RS, Bollinger RC, **J Acquir ImmuneDefic Syndr 2006; 41(3): 317-373**
29. *"High HIV Prevalence Among a High-Risk Subgroup of Women Attending Sexually Transmitted Infection Clinics in Pune, India."* Shruti H Mehta, Amita Gupta, Seema Sahay, **Sheela VGodbole**, Smita N Joshi, Steven J Reynolds, David D Celentano, Arun Risbud, Sanjay M Mehendale, Robert C Bollinger. **J Acquir ImmuneDefic Syndr. 2006 Jan; 41(1):75-80**
30. *"Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-uninfected women in Pune, India."*Joshi SN, Katti U, **Godbole S**, Bharucha K, B KK, Kulkarni S, Risbud A, Mehendale S.**Trans R Soc Trop Med Hyg. 2005 Oct; 99(10):769-74**
31. *"HIV/AIDS epidemic in India: risk factors, risk behaviours and strategies for prevention and control."***Sheela Godbole& Sanjay Mehendale Indian J Med Res. 2005 Apr;121(4):356-68**
32. *"Fluconazole resistant non-albicans vaginal yeast in HIV seronegative women with vaginal discharge in Pune, India."* R Kairon, **S Godbole**, S Kulkarni, M Ghate, S Sane, A Shrotri, K Bharucha, S Mehendale, A Risbud. **Int J Infect Dis. 2004 Jul; 8(4):251-2**
33. *"Agenda for Action: Research Priorities in HIV/AIDS in Maharashtra, India."*
A report for Avert Society Maharashtra: a Joint project of NACO, Govt. of Maharashtra and USAID. Facilitators and Editors: Dr. Seema Sahay and **Dr. Sheela Godbole**

***As a Study Team Member**

34. *Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J,Laloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W,Rooney JF, Uy*

J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012 Aug;9(8):e1001290. Epub 2012 Aug 14. PMID: 22936892, PMCID: PMC3419182

Abstracts Presented in Conferences: 30

Abstracts Published in Journal of International AIDS Society: 6